DrugPatentWatch Database Preview
Astrazeneca Pharms Company Profile
» See Plans and Pricing
What is the competitive landscape for ASTRAZENECA PHARMS, and when can generic versions of ASTRAZENECA PHARMS drugs launch?
ASTRAZENECA PHARMS has nineteen approved drugs.
There are fifty-seven US patents protecting ASTRAZENECA PHARMS drugs.
There are one thousand two hundred and one patent family members on ASTRAZENECA PHARMS drugs in sixty-seven countries and one hundred and fifty supplementary protection certificates in nineteen countries.
Summary for Astrazeneca Pharms
International Patents: | 1201 |
US Patents: | 57 |
Tradenames: | 16 |
Ingredients: | 15 |
NDAs: | 19 |
Drugs and US Patents for Astrazeneca Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Pharms | IRESSA | gefitinib | TABLET;ORAL | 206995-001 | Jul 13, 2015 | RX | Yes | Yes | Start Trial | Start Trial | |||||
Astrazeneca Pharms | DALIRESP | roflumilast | TABLET;ORAL | 022522-002 | Jan 23, 2018 | RX | Yes | No | 9,468,598 | Start Trial | Y | Start Trial | |||
Astrazeneca Pharms | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | 9,050,308 | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Astrazeneca Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astrazeneca Pharms | NEXIUM | esomeprazole magnesium | CAPSULE, DELAYED REL PELLETS;ORAL | 021153-002 | Feb 20, 2001 | 7,411,070*PED | Start Trial |
Astrazeneca Pharms | PRILOSEC OTC | omeprazole magnesium | TABLET, DELAYED RELEASE;ORAL | 021229-001 | Jun 20, 2003 | 5,753,265 | Start Trial |
Astrazeneca Pharms | PULMICORT RESPULES | budesonide | SUSPENSION;INHALATION | 020929-001 | Aug 8, 2000 | 6,899,099*PED | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ASTRAZENECA PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Capsules | 20 mg | ➤ Subscribe | 2007-03-19 |
➤ Subscribe | Tablets | 90 mg | ➤ Subscribe | 2015-07-20 |
➤ Subscribe | Tablets | 500 mcg | ➤ Subscribe | 2015-03-02 |
➤ Subscribe | Tablets | 50 mg, 150 mg and 400 mg | ➤ Subscribe | 2007-02-12 |
➤ Subscribe | Delayed-release | 20 mg and 40 mg | ➤ Subscribe | 2005-08-05 |
➤ Subscribe | For Injection | 20 mg/vial and 40 mg/vial | ➤ Subscribe | 2009-11-23 |
➤ Subscribe | Inhalation Suspension | 1 mg/2 mL | ➤ Subscribe | 2010-05-28 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2012-03-30 |
➤ Subscribe | Tablets | 60 mg | ➤ Subscribe | 2015-09-30 |
➤ Subscribe | Tablets | 25 mg | ➤ Subscribe | 2005-08-12 |
➤ Subscribe | Tablets | 100 mg, 200 mg and 300 mg | ➤ Subscribe | 2006-02-21 |
➤ Subscribe | Delayed-release for Oral Suspension | 2.5 mg and 5 mg | ➤ Subscribe | 2018-09-24 |
➤ Subscribe | Inhalation Suspension | 0.25 mg/2 mL and 0.5 mg/2 mL | ➤ Subscribe | 2005-09-15 |
International Patents for Astrazeneca Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 176013 | Start Trial |
South Korea | 20030059811 | Start Trial |
European Patent Office | 3000810 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Astrazeneca Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1482932 | C20190010 00281 | Estonia | Start Trial | PRODUCT NAME: BINIMETINIIB;REG NO/DATE: EU/1/18/1315 24.09.2018 |
2673237 | 2019C/519 | Belgium | Start Trial | PRODUCT NAME: LOKELMA - CYCLOSILICATE DE ZIRCONIUM SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326 |
1633724 | 596 | Finland | Start Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.